De Rose A F, Giglio M, Traverso P, Lantieri P, Carmignani G
Department of Urology, S. Martino Hospital, University of Genoa, Italy.
Int J Impot Res. 2002 Feb;14(1):50-3. doi: 10.1038/sj.ijir.3900815.
The purpose of this work was to investigate the efficacy and safety of sildenafil in combination with doxazosin for the treatment of non-organic erectile dysfunction in patients who did not respond to sildenafil. We enrolled 28 patients with non-organic erectile dysfunction, for whom 3 months of sildenafil monotherapy had failed. They were divided in two random and homogeneous groups: 14 were treated with doxazosin (4 mg daily) and sildenafil (100 mg 1 h before sexual intercourse); the other 14 patients received sildenafil and placebo. The results were assessed by means of the IIEF questionnaire before the beginning of the study, after 30 days of therapy and after 60 days. Of the 14 patients treated with doxazosin and sildenafil, 11 (78.6%) showed a statistically significant increase of IIEF; in the placebo group, only one patient (7.1%) recorded a significant IIEF increase. The differences observed in the two groups were statistically very significant (P=0.0016). Blood pressure did not show significant alterations. Side effects were minimal and even present during sildenafil monotherapy. The combination therapy with sildenafil and doxazosin resulted in the safe and effective treatment of men with non-organic erectile dysfunction for whom sildenafil alone had failed.
这项研究的目的是调查西地那非联合多沙唑嗪治疗对西地那非无反应的非器质性勃起功能障碍患者的疗效和安全性。我们招募了28例非器质性勃起功能障碍患者，他们接受3个月的西地那非单药治疗均失败。将他们随机分为两组，每组14人：一组接受多沙唑嗪（每日4mg）和西地那非（性交前1小时服用100mg）治疗；另一组14例患者接受西地那非和安慰剂治疗。在研究开始前、治疗30天后和60天后，通过国际勃起功能指数（IIEF）问卷对结果进行评估。在接受多沙唑嗪和西地那非治疗的14例患者中，11例（78.6%）的IIEF有统计学显著升高；在安慰剂组中，只有1例患者（7.1%）的IIEF有显著升高。两组间观察到的差异具有统计学极显著性（P = 0.0016）。血压未显示出显著变化。副作用极小，且在西地那非单药治疗期间也有出现。西地那非和多沙唑嗪联合治疗对单用西地那非治疗失败的非器质性勃起功能障碍男性患者是安全有效的。
